CELL-EASY/EMERCELL
22.9.2022 15:01:34 CEST | Business Wire | Press release
Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercell’s lead product.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005449/en/
Emercell has developed a platform technology to produce off-the-shelf natural killer (NK) cells. NK cells are highly potent immune effectors, used alone as monotherapy, or in combination with therapeutic antibodies, or are genetically engineered to produce Chimeric Antigen Receptor (CAR)-NK cells for the treatment of hematological malignancies and solid tumors. NK-001 is an optimized cell therapy product composed of highly activated and alloreactive allogeneic NK cells. Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.
Cell-Easy is an analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in the production of Gene-modified Cell and Cell Therapy products. Cell-Easy’s facilities are located in Toulouse including state-of-the-art controlled environment suites optimized for developing manufacturing and analytical processes, proceed to environmental and material Quality Control, and execute cGMP manufacturing, fill & finish, long-term storage of Advanced Therapy Medicinal Products (ATMPs) compliant with all the requirements of regulatory standards and cGMP guidelines.
Emercell has selected Cell-Easy as a long-term CDMO partner for the scale-up and manufacturing operations of its allogeneic NK cell-based product, with the objective to enter clinical phase in 2023. Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP.
“We are very pleased to collaborate with Cell-Easy on the final stages of development and GMP manufacturing of our flagship product, NK-001“, said Patrick Henno, President of Emercell.” We are looking forward to a successful and long-lasting collaboration as a key element of our development strategy. Moreover, Cell-Easy and Emercell are located in the Occitanic Region and the partnership fits perfectly with the Region’s objectives regarding the development and production of new products in the field of biotherapies, and particularly in the field of immunotherapy.
In a very competitive European landscape, we are delighted that Emercell has chosen us as their privileged CDMO Partner for their first immune-oncology approach using NK-cells”, said Guillaume Costecalde, President of Cell-Easy. “Cell-Easy CDMAO’s original approach and the team’s reactivity combined with our state-of-the-art facility allow us once again to convince ambitious ATMP developers such as Emercell to secure their development.”
About Emercell
Emercell is an oncology company developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's R&D activities are located at the IRMB (Institute of Regenerative Medicine and Biotherapies) at the Saint-Éloi University Hospital Center, Montpellier, France. Emercell's lead drug candidate, NK-001, is intended, among others, for the treatment of lymphoma patients who are refractory to conventional therapies. It is a patented process for pre-activating and amplifying allogeneic NK cells. Emercell collaborates with numerous industrial and academic partners. The company has received the support of the Occitanie Region (ADI) and Bpifrance and has obtained a FUI (financing). Emercell is a member of Eurobiomed.
About Cell-Easy
Cell-Easy developed a unique vision of CDMO dedicated to the production of Cell and Gene modified Cell Therapy products. This integrated concept is called CDMAO. Beyond CDMO, CDMAO is not only focused on Development & Manufacturing. CDMAO is positioned as a real partner for helping Biotech & Pharma to bridge the gap between preclinical and clinical development with in-depth expertise on regulatory process scale-up and analytics.
Cell-Easy offers customized process development, process scale-up, cGMP manufacturing and unique analytical services for immune cells (engineered CAR-T, NK, …cells, and non-engineered cells) and adult stem cells (MSCs, iPSCs and Exosomes) both in Immuno-Oncology and Regenerative Medicine fields.
Cell-Easy is a trusted partner and brings today the infrastructure and know-how while ensuring your projects are delivered on time and budget. Supported by highly motivated and experienced people in the Cell Therapy field, Cell-Easy is committed to driving service excellence and actively contribute to a “Bench to Bedside” culture, putting the healthcare of patients at the center of everything.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005449/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Wealth Firms Build Private Markets Capability Faster Than They Communicate It, Peregrine Report Finds20.10.2026 10:15:00 CEST | Press release
Capability outpaces communication: 73% of the 30 firms show visible private markets engagement, yet only 40% have a dedicated landing page explaining it to clients Swiss private banks set the benchmark: 70% maintain dedicated private markets destinations, led by Julius Baer, UBP, Pictet and Lombard Odier Visibility is concentrated: five firms generate half of all wealth management media coverage, and alternatives just 7% Europe's leading wealth managers have built genuine private markets capability but most have yet to explain it to the clients they built it for, according to The Wealth 30, a new report from Peregrine Communications. The study analyses how 30 leading UK and European wealth managers and private banks position private markets. It concludes that communication, not product, is now the biggest barrier to differentiation in the wealth channel. Capability outpaces explanation 73% of the Wealth 30 engage in private markets yet only 40% operate a dedicated landing page explaini
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia’s Automotive Sector20.10.2026 10:00:00 CEST | Press release
Global AI-first cloud communications platform Infobip strengthens its collaboration with Yamaha Indonesia Motor Manufacturing (YIMM) to transform customer engagement through WhatsApp-powered conversational experiences designed to drive stronger personalization and faster customer interactions. As Indonesia’s consumers increasingly adopt digital-first purchasing behaviors, Yamaha Indonesia is evolving how it connects with customers across the buying journey. Today’s motorcycle buyers often research products through Yamaha’s social media, websites, and video reviews on YouTube before visiting dealerships, raising expectations for brands to deliver fast, seamless, and highly personalized communication. For more than two years, Infobip has supported Yamaha Indonesia in building connected customer engagement strategies that integrate WhatsApp across the company’s wider digital ecosystem, including its websites, social media platforms, and customer touchpoints. The collaboration reflects the
BRG Survey Finds 71% of Competition Lawyers Say Global Antitrust Policies Grew More Fragmented over Past Year20.10.2026 09:00:00 CEST | Press release
BRG's inaugural Global Antitrust & Competition Report surveys 155 senior attorneys across 15 countries, mapping a new era of enforcement shaped by expanding priorities and mounting political stakes. Global antitrust enforcement is pulling apart along national lines, with 71% of senior competition attorneys reporting that policy became more fragmented across jurisdictions over the past 12 months, according to BRG’s inaugural Global Antitrust & Competition Report. Nearly four in five (78%) also cite cross-border antitrust requirements as a significant or recurring challenge. The report draws on a survey of 155 senior antitrust and competition attorneys across the U.S., Europe and Asia-Pacific (APAC) and in-depth interviews with 18 leading lawyers. It also finds that about 60% of respondents expect antitrust enforcement to expand in scope and intensity over the next 12 months. “Domestic politics and geopolitical considerations increasingly influence the application of competition law acro
Finsei Selects Thredd to Power New Debit Offering20.10.2026 09:00:00 CEST | Press release
Partnership brings scalable payment processing, digital wallet capabilities and advanced fraud controls to integrated business finance platform Thredd, the AI-first issuer processing platform, today announced a new partnership with Finsei, a London-based payments company, to power the processing infrastructure behind Finsei’s new Mastercard debit offering. The partnership reflects a shared focus on simplifying an increasingly complex payments environment. Businesses operating across markets often rely on multiple providers to manage accounts, payments, foreign exchange, cards and expenses. Finsei is designed to bring those capabilities together, while Thredd provides the underlying payment technology and infrastructure needed to deliver a secure, digital-first debit experience at scale. At launch, physical and virtual cards will be available, followed by both Apple Pay and Google Pay. “Businesses increasingly expect their financial tools to work together rather than operate as a collec
Murata Develops World’s Smallest 008004-inch Size (0.25mm × 0.125mm) NTC Thermistor for Space-Constrained Temperature Sensing20.10.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces the development of the world’s smallest* 008004-inch size (0.25mm × 0.125mm) NTC thermistor, the NCU01 series. Compared with Murata’s previous smallest 01005-inch size (0.4mm × 0.2mm) product, the new series reduces mounting area by approximately 60% while achieving equivalent temperature-sensing performance, with resistance tolerance of ±1% and B-constant tolerance of ±1%. Its ultra-compact size enables temperature sensing to be positioned in increasingly restricted spaces and closer to heat-generating components, supporting more accurate and responsive thermal monitoring in smartphones, wearable devices, and other densely integrated electronic devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019189089/en/ [Murata Manufacturing Co., Ltd.] World’s smallest 008004-inch size (0.25mm × 0.125mm) NTC thermistor Murata plans to begin sample shipm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom